All In Biotech

Drug Trial Radar · NCT06833307

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Feb 2025

Primary completion

Jul 2026

Study completion Aug 2026

Sponsor

Sponsor type
Industry
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy, safety of subcutaneous SHR-1314 in pediatric patients of age 6 to \<18 years with moderate-to-Severe plaque psoriasis

Conditions

  • Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis

Interventions

  • SHR-1314Drug

    SHR-1314: dose 1 SHR-1314:dose 2 SHR-1314:dose 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety assessment including adverse events at Week 16Time frame: Week 16
  2. PK parameters: Cmax at Week 12Time frame: Week 12

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Capital Medical University Affiliated Children's Hospital

    Beijing, Beijing Municipality, China

  • Shanghai Huashan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.